H.C. Wainwright analyst Robert Burns raised the firm’s price target on Cogent Biosciences (COGT) to $55 from $52 and keeps a Buy rating on the shares following the Q1 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences announces preclinical data from KRAS, ErbB2 programs
- Bezuclastinib’s Strong Phase 3 GIST Data and NDA Catalyst Support Buy Rating and $52 Target
- Cogent Biosciences submits bezuclastinib new drug application to the FDA
- Cogent Biosciences Advances CGT6297 Into First-in-Human Trial for PIK3CA-Driven Cancers
- Cogent Biosciences assumed with a Buy at Jefferies